# Alain Parthoens

> Alain Parthoens is a Series A investor at Newton Biocapital backing Biotechnology and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Newton Biocapital](https://shizune.co/investors/profile/newton-biocapital)
- Location: Brussels, Belgium
- Total investments: 7
- Last investment: Dec 2025
- Lead investor: 86%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/alain-parthoens-3bab398/?originalSubdomain=be

Alain Parthoens is a Series A investor at Newton Biocapital in Brussels focused on Biotechnology and Medical. Alain Parthoens has more than twenty years of international experience in the food and life sciences businesses including marketing for Nestlé, business analysis for Kemira, product development and strategic planning for Monsanto and consultancy in R&D for pharmaceutical companies with PriceWaterhouseCoopers in London.Before he joinedVesalius Biocapital, Alain was an Investment Director at ING Corporate Investments in Belgium. Since 2001, he has been the lead investor for the private placement of Unibioscreen (oncology, EUR 19 m raised), MTI (stress resistant corn germplasm, EUR 14 m raised), OncoMethylome Sciences (cancer diagnostics, creation of the company, EUR 29 m raised in round A & B followed in June 2006 by a EUR 28 m IPO on Euronext), TiGenix (regenerative medicine, EUR 12 m raised, followed by EUR 16 m pre-IPO round and an IPO of EUR 40 m in March 2007) and most recently Bienca (food preservation, EUR 5 m raised). He was also actively involved in the private placement of BioAlliance (Paris, EUR 12 m private placement, followed by a successful EUR 30 m IPO on Euronext in December 2005) and participated in the refinancing of CropDesign and its trade sale to BASF.He was the chairman of the Belgian Venture and Private Equity Association and BOD member of Unibioscreen, Oncomethylome Sciences, Apitope, Bienca and Promethera.Alain holds an MSc in agronomy and speciality biochemistry from the Université Catholique de Louvain, an MSc in finance and computer sciences from the Université Libre de Bruxelles and a management degree from the Solvay Business School (CEPAC).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Medical | 2 | 29% |
| Therapeutics | 2 | 29% |
| Pharmaceutical | 2 | 29% |
| Biopharma | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series B | 1 | 14% |
| Funding Round | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 29% |
| Japan | 1 | 14% |
| Belgium | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bioxodes | Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration withacademic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland.The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures. | $6.4M | Series A | Dec 10, 2025 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. |  |  | Nov 11, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | $10.6M | Series A | Nov 11, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. |  | Series A | Jan 23, 2023 |  |
| EditForce | EditForce develops drugs and seeds by using nucleic acid (DNA/RNA) manipulation technologies. | $7.3M | Venture - Series Unknown | May 26, 2021 |  |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $7.7M | Series B | Nov 06, 2019 |  |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $16.8M | Series B | Oct 17, 2018 |  |

7 of 7 investments shown.

## Co-investors
- [Good Growth Capital](https://shizune.co/investors/profile/good-growth-capital) — VC Fund, 3 deals together
- [InvestSud](https://shizune.co/investors/profile/investsud-9c11) — VC Fund, 2 deals together
- [Karista](https://shizune.co/investors/profile/karista) — VC Fund, 2 deals together
- [Okeanos](https://shizune.co/investors/profile/riverbend-capital) — VC Fund, 2 deals together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 2 deals together
- [CMS Medical Venture Investment](https://shizune.co/investors/profile/cms-medical-venture-investment) — VC Fund, 1 deal together

## About Newton Biocapital

VC Fund · Brussels, Belgium

Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases.Their approach as lead investor is to support promising start-up projects as well as neglected or undervaluedlate-stage projects, in order to mitigate the risks and to create investor value. The leadership team consi.sts of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects.

4 contacts available at Newton Biocapital.

| Name | Title | Profile |
| --- | --- | --- |
| Els Hubloux | Partner | https://shizune.co/investors/profile/els-hubloux |
| Goro Takeda | Managing Partner | https://shizune.co/investors/profile/goro-takeda |
| Toshiyuki Mori | Partner, Tokyo | https://shizune.co/investors/profile/toshiyuki-mori |
| Alain Parthoens | Managing Partner and Founder | https://shizune.co/investors/profile/alain-parthoens |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alain Parthoens invest in?

Alain Parthoens invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alain Parthoens last invest?

The most recent investment recorded for Alain Parthoens closed in Dec 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co